$PLRX
PLIANT THERAPEUTICS, INC.

2022 Q4 Form 10-Q Financial Statement

#000174647322000031 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $1.965M $1.482M $1.600M
YoY Change -1.7% -7.38% -66.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.25M $8.823M $7.671M
YoY Change 81.63% 15.02% 67.12%
% of Gross Profit
Research & Development $25.11M $24.61M $21.05M
YoY Change 33.93% 16.88% 24.69%
% of Gross Profit
Depreciation & Amortization $455.0K $500.0K $400.0K
YoY Change 8.85% 25.0% 33.33%
% of Gross Profit
Operating Expenses $39.37M $33.43M $28.72M
YoY Change 48.0% 16.38% 33.75%
Operating Profit -$31.95M -$27.11M
YoY Change 17.83% 62.73%
Interest Expense $2.340M $1.332M $68.00K
YoY Change 3341.18% 1858.82% -2.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$35.06M -$30.62M -$27.05M
YoY Change 42.92% 13.2% 63.61%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$35.06M -$30.62M -$27.05M
YoY Change 42.92% 13.2% 63.57%
Net Earnings / Revenue -1784.22% -2065.79% -1690.31%
Basic Earnings Per Share -$0.65 -$0.75
Diluted Earnings Per Share -$0.72 -$0.65 -$0.75
COMMON SHARES
Basic Shares Outstanding 48.76M shares 48.68M shares 35.91M shares
Diluted Shares Outstanding 46.80M shares 35.91M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $331.2M $360.2M $221.0M
YoY Change 65.1% 62.97% -24.81%
Cash & Equivalents $33.69M $44.62M $45.23M
Short-Term Investments $297.5M $315.6M $175.8M
Other Short-Term Assets $7.058M $4.159M $5.847M
YoY Change 4.35% -28.87% -10.05%
Inventory
Prepaid Expenses
Receivables $1.983M $1.482M $1.610M
Other Receivables $83.00K $83.00K $83.00K
Total Short-Term Assets $340.3M $366.0M $228.6M
YoY Change 62.49% 60.1% -25.71%
LONG-TERM ASSETS
Property, Plant & Equipment $4.486M $4.799M $4.706M
YoY Change -2.61% 1.98% 14.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $394.0K $397.0K $831.0K
YoY Change -52.98% -52.23% 66.2%
Total Long-Term Assets $10.30M $11.22M $5.537M
YoY Change -12.5% 102.56% 20.37%
TOTAL ASSETS
Total Short-Term Assets $340.3M $366.0M $228.6M
Total Long-Term Assets $10.30M $11.22M $5.537M
Total Assets $350.6M $377.2M $234.1M
YoY Change 58.49% 61.11% -25.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.580M $3.206M $2.605M
YoY Change -46.82% 23.07% -15.97%
Accrued Expenses $22.33M $20.31M $10.32M
YoY Change 86.25% 96.76% 30.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.649M
YoY Change
Total Short-Term Liabilities $23.91M $26.16M $12.93M
YoY Change 42.08% 102.41% 17.5%
LONG-TERM LIABILITIES
Long-Term Debt $9.929M $14.03M $0.00
YoY Change 86.46%
Other Long-Term Liabilities $3.429M $4.126M $756.0K
YoY Change 445.77% -24.4%
Total Long-Term Liabilities $13.36M $14.03M $756.0K
YoY Change 1755.29% -24.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.91M $26.16M $12.93M
Total Long-Term Liabilities $13.36M $14.03M $756.0K
Total Liabilities $37.27M $40.19M $13.68M
YoY Change 68.22% 193.74% 14.01%
SHAREHOLDERS EQUITY
Retained Earnings -$338.4M -$303.4M -$190.6M
YoY Change 57.33% 59.19%
Common Stock $653.7M $642.8M $411.0M
YoY Change 57.77% 56.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $313.3M $337.0M $220.4M
YoY Change
Total Liabilities & Shareholders Equity $350.6M $377.2M $234.1M
YoY Change 58.49% 61.11% -25.03%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$35.06M -$30.62M -$27.05M
YoY Change 42.92% 13.2% 63.57%
Depreciation, Depletion And Amortization $455.0K $500.0K $400.0K
YoY Change 8.85% 25.0% 33.33%
Cash From Operating Activities -$31.24M -$18.50M -$22.51M
YoY Change 57.26% -17.82% 42.47%
INVESTING ACTIVITIES
Capital Expenditures $166.0K -$696.0K -$480.0K
YoY Change -128.04% 45.0% 45.45%
Acquisitions
YoY Change
Other Investing Activities $20.19M -$177.6M $32.58M
YoY Change -23.46% -644.98% -131.1%
Cash From Investing Activities $20.02M -$178.3M $32.10M
YoY Change -22.34% -655.3% -130.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 284.0K 216.3M 449.0K
YoY Change -44.96% 48073.05% -119.03%
NET CHANGE
Cash From Operating Activities -31.24M -18.50M -22.51M
Cash From Investing Activities 20.02M -178.3M 32.10M
Cash From Financing Activities 284.0K 216.3M 449.0K
Net Change In Cash -10.93M 19.55M 10.04M
YoY Change -269.93% 94.71% -108.15%
FREE CASH FLOW
Cash From Operating Activities -$31.24M -$18.50M -$22.51M
Capital Expenditures $166.0K -$696.0K -$480.0K
Free Cash Flow -$31.40M -$17.80M -$22.03M
YoY Change 62.95% -19.19% 42.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001746473
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39303
dei Entity Registrant Name
EntityRegistrantName
PLIANT THERAPEUTICS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4272481
dei Entity Address Address Line1
EntityAddressAddressLine1
260 Littlefield Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
481-6770
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48759419 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44617000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51665000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
315624000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
148931000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1482000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1998000 usd
CY2022Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83000 usd
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4159000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6764000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
365965000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
209441000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4799000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4606000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6020000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6330000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
397000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
838000 usd
CY2022Q3 us-gaap Assets
Assets
377181000 usd
CY2021Q4 us-gaap Assets
Assets
221215000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3206000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2971000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20306000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11991000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26161000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2649000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1869000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16831000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4126000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5325000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
9900000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2022Q3 us-gaap Liabilities
Liabilities
40187000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
22156000 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48749842 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48749842 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36083301 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36083301 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
642795000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
414348000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303352000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215091000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2454000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-201000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
336994000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199059000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
377181000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221215000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1482000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1610000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7720000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5573000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24606000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21052000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71822000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58797000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8823000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7671000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25698000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19712000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
33429000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
28723000 usd
us-gaap Operating Expenses
OperatingExpenses
97520000 usd
us-gaap Operating Expenses
OperatingExpenses
78509000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31947000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27113000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-89800000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-72936000 usd
CY2022Q3 plrx Interest And Other Income Net
InterestAndOtherIncomeNet
1332000 usd
CY2021Q3 plrx Interest And Other Income Net
InterestAndOtherIncomeNet
68000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30615000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27045000 usd
plrx Interest And Other Income Net
InterestAndOtherIncomeNet
1539000 usd
plrx Interest And Other Income Net
InterestAndOtherIncomeNet
204000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27045000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72732000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88261000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72732000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2253000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46799058 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35906303 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39735342 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35787022 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46799058 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35906303 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39735342 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35787022 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27045000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72732000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1195000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1195000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2253000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-8000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31810000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27055000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90514000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72740000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199059000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3531000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-749000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28100000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
173793000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
446000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3403000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-309000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29546000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
147788000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
200000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
808000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4808000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1195000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
215400000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
336994000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
283061000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1370000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2578000 usd
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22856000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
264169000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2280000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1700000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
372000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22831000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
243980000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2811000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27045000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
220440000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72732000 usd
us-gaap Depreciation
Depreciation
1368000 usd
us-gaap Depreciation
Depreciation
1117000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11743000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7669000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1260000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
863000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
264000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-914000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-516000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7669000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2605000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
900000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-441000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
380000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
254000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
401000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8315000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
719000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1369000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-918000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63392000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55578000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
289402000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
181967000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
120770000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
231244000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1594000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1361000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170226000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47916000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1305000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2443000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
786000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
432000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
100000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
150000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
216201000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
226570000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2011000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7048000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5651000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51665000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50882000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44617000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45231000 usd
us-gaap Interest Paid Net
InterestPaidNet
332000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
330000 usd
plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
0 usd
plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
7000 usd
plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
14000 usd
plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
17000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2253000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-8000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
950000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4159000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6764000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to stock-based compensation expense and accruals for research and development costs. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
345514000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
2455000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343060000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
183958000 usd
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000 usd
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
202000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
183757000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11185000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9625000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6386000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5019000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4799000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4606000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
500000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
400000 usd
us-gaap Depreciation
Depreciation
1400000 usd
us-gaap Depreciation
Depreciation
1100000 usd
CY2022Q3 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
2258000 usd
CY2021Q4 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
2819000 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
6000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2585000 usd
CY2022Q3 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
936000 usd
CY2021Q4 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
819000 usd
CY2022Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
752000 usd
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
385000 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
207000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
156000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4712000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5216000 usd
CY2022Q3 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14689000 usd
CY2021Q4 plrx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5868000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
905000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
907000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20306000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11991000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
0 usd
CY2021 us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5455000 usd
CY2022Q3 plrx Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
4545000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 usd
CY2022Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
139000 usd
CY2022Q3 plrx Long Term Debt Accretion Of Final Payment
LongTermDebtAccretionOfFinalPayment
39000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
9900000 usd
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 plrx Number Of Classes Of Stock Authorized
NumberOfClassesOfStockAuthorized
2 class
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10688091 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8467491 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4808000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2811000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11743000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7669000 usd
CY2018Q1 plrx Period Of Base Rent Abatement
PeriodOfBaseRentAbatement
P2M
CY2018Q1 plrx Base Rent Abated Amount
BaseRentAbatedAmount
200000 usd
CY2022Q3 plrx Base Rent Abated Amount
BaseRentAbatedAmount
100000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 plrx Valuation Allowance As Percentage On Deferred Tax Assets
ValuationAllowanceAsPercentageOnDeferredTaxAssets
1
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
plrx Contractual Arrangements Cancellation Period
ContractualArrangementsCancellationPeriod
P30D
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
700000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
700000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1800000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
400000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
700000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1900000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1900000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
773000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3080000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2422000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1203000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7478000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
703000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2649000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4126000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5997821 shares
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 usd
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3729963 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30615000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27045000 usd
us-gaap Net Income Loss
NetIncomeLoss
-88261000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72732000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30615000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30615000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27045000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27045000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88261000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-88261000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72732000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72732000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46799058 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35906303 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39735342 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35787022 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46799058 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35906303 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39735342 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35787022 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03

Files In Submission

Name View Source Status
0001746473-22-000031-index-headers.html Edgar Link pending
0001746473-22-000031-index.html Edgar Link pending
0001746473-22-000031.txt Edgar Link pending
0001746473-22-000031-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plrx-20220930.htm Edgar Link pending
plrx-20220930.xsd Edgar Link pending
plrx-20220930xex311.htm Edgar Link pending
plrx-20220930xex312.htm Edgar Link pending
plrx-20220930xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
plrx-20220930_cal.xml Edgar Link unprocessable
plrx-20220930_def.xml Edgar Link unprocessable
plrx-20220930_lab.xml Edgar Link unprocessable
plrx-20220930_pre.xml Edgar Link unprocessable
plrx-20220930_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable